Abstract
Our aim was to evaluate the safety and assess the efficacy of pirfenidone, an antifibrotic drug, in patients with primary sclerosing cholangitis (PSC). Twenty-four patients with PSC were enrolled in this pilot study. Oral pirfenidone, 2400 mg daily, was given for one year. Liver biochemistries were determined at three-month intervals. The Mayo risk score was calculated, and liver biopsy and endoscopic cholangiography were performed at entry and at one year of treatment. No significant changes in liver biochemistries were noted at the end of the treatment period or at any of the three-month intervals. The Mayo risk score did not change significantly, and no significant changes were noted in the degree of inflammation, fibrosis, histologic stage of disease, or cholangiographic findings at the end of the treatment period. Adverse events occurred in 20/24 (83%) patients, but disappeared shortly after pirfenidone was discontinued. Pirfenidone did not benefit patients with PSC, and it was frequently associated with adverse events. The results of this pilot study discourage further trials of pirfenidone in patients with PSC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Angulo P, Lindor KD: Primary sclerosing cholangitis. Hepatology 30:325–332, 1999
Zhang S, Shiels IA, Ambler JS, et al: Pirfenidone reduces fibronectin synthesis by cultured human retinal pigmented epithelial cells. Aust New Zeland Ophthalmol 26:S74–S76, 1998
Shimizu T, Fukagawa M, Kuroda T, et al: Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int 52:S239–S243, 1997
Shimizu T, Kuroda T, Hata S, et al: Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 54:99–109, 1998
Gurujeyalakshmi G, Hollinger MA, Giri SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translation level. Am J Physiol 276:L311–L318, 1999
Cain WC, Stuart RW, Lefkowitz DL, et al: Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 20:685–695, 1998
Kaneko M, Inoue H, Nakazawa R, et al: Pirfenidone induces intracellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol 113:72–76, 1998
Lee BS, Margolin SB, Nowak RA: Pirfenidone: A novel pharmacological agent that inhibits leiomyoma cell proliferation and chollagen production. J Clin Endocrinol Metab 83:219–223, 1998
Shetlar MR, Shetlar DJ, Bloom RF, et al: Involution of keloid implants in athymic mice treated with pirfenidone or with triamcinolone. J Lab Clin Med 132:491–496, 1998
Raghu G, Johnson C, Lockhart D, et al: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone. Results of a prospective, open-label phase II study. Am J Crit Care Med 159:1061–1069, 1999
Suga H, Teraoka S, Ota K, et al: Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxic Pathol 47:287–291, 1995
Al-Took S, Tulandi T: Effects of pirfenidone and dermoid cyst fluid on adhesion formation. Fertil Steril 69:341–343, 1998
Kim WR, Poterucha JJ, Wiesner RH, et al: The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 29:1643–1648, 1999
Ludwig J, LaRusso NF, Wiesner RH: Primary sclerosing cholangitis. In liver Pathology—Contemporary Issues in Surgical Pathology. RL Peters, JR Craig (eds). New York, Churchill Livingstone, pp 193–213, 1986
MacCarty RL, LaRusso NF, Wiesner RH, et al: Primary sclerosing cholangitis: Findings on cholangiography and pancreatography. Radiology 149:39–44, 1983
Margolin SB: Investigational new drug brochure “Pirfenidone'. ” Marnac, Inc., Dallas, Texas. January 1996
Wiesner RH, Grambsch PM, Dickson ER, et al: Primary sclerosing cholangitis: Natural history, prognostic factors and survival analysis. Hepatology 10:430–436, 1989
Dickson ER, Murtaugh PA, Wiesner RH, et al: Primary sclerosing cholangitis: Refinement and validation of survival models. Gastroenterology 103:1893–1901, 1992
Farrant JM, Hayllar KM, Wilkinson ML, et al: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100:1710–1717, 1991
Broome U, Olsson R, Loof L, et al: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38:610–615, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Angulo, P., MacCarty, R.L., Sylvestre, P.B. et al. Pirfenidone in the Treatment of Primary Sclerosing Cholangitis. Dig Dis Sci 47, 157–161 (2002). https://doi.org/10.1023/A:1013240225965
Issue Date:
DOI: https://doi.org/10.1023/A:1013240225965